LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Phase 1 dosing is expected to finish by the end of 2025
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Subscribe To Our Newsletter & Stay Updated
